Genmab is the winner of the very first DenmarkBridge Award
The Award was presented by His Royal Highness Crown Prince Frederik at the Annual Meeting of The Danish Growth Fund on 3 May.
Award winner 2017
The DenmarkBridge Award pays tribute to companies, organisations or individuals who have the courage to think bigger, aim for the unreachable, and deliver on these promises – a moonshot-mentality. That is exactly what characterizes Genmab, according to the DenmarkBridge Award Jury.
“Running a biotech-company is an innovation-intensive business. There are large returns when products have a significant effect and are approved for use. But before this, much R&D needs to be carried out. It takes persistence and ambition to make it happen, and being able to deliver on this is a trademark of Genmab,” says Christian Motzfeldt, chairman DenmarkBridge.
Genmab is honored to win the DenmarkBridge Award 2017.
”We are humbled and honored winning this award. At Genmab we have a bold vision that by 2025 our own cancer product will have transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies. Our international team has a moonshot mindset, and it is their talent and passionate determination that will ensure we can achieve our goals and continue to build an innovation powerhouse,” says Jan van de Winkel, CEO at Genmab.
See the video with Genmab and the other four finalists for the DenmarkBridge Award 2017.
Genmab is an international biotechnology company specializing in the development of antibody treatments of cancer. The company has committed to this by developing solutions that only target the sick cells, and not the healthy cells of a cancer-infected body. Therefore the company believes that patients should not suffer from side-effects to the same extent as earlier.
The company is based in Denmark and has entered the American market with the product Darzalex.
Genmab was listed in 2000 – only one year after the company’s establishment in 1999.
About the DenmarkBridge Award
The DenmarkBridge Award has the following characteristics:
- The award will be handed out annually
- The award is honorary
- The selection criteria are: Ambition, innovation and technology, commercial impact, network effect
- Nominations that meet the criteria can be made public on denmarkbridge.dk
- The board of DenmarkBridge serves as jury for the award
- The winner will be announced by HRH The Crown Prince at the Annual Meeting of the Danish Growth Fund on 3 May 2017
Get in touch
Do not hesitate to contact us. The Danish Growth Fund functions as secretariat for DenmarkBridge. We provide services to the board of directors and founding members accordingly, and are ready to answer any questions you may have.
200 Page Mill Rd, Ste 100
94306 Palo Alto, California
United States of America
The Danish Growth Fund